事業成果物：
研究成果は、国内外の学会などに報告し、あるいは原著論文として論文発表を行った。学会発表などは省略し、英文原著論文のみを記載する。

研究１　腫瘍細胞社会の解析と阻害剤スクリーニング
1.Kawakami R, Mashima T, Kawata N, Kumagai K, Migita T, Sano T, Mizunuma N, Yamaguchi K, Seimiya H. ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer.
Cancer Sci, 111: 962-973, 2020.
2.Jang MK, Mashima T, Seimiya H. Tankyrase inhibitors target colorectal cancer stem cells via AXIN-dependent downregulation of c-KIT tyrosine kinase.
Mol Cancer Ther, 19: 765-776, 2020.
3.Suenaga M, Wakatsuki T, Mashima T, Ogura M, Ichimura T, Shinozaki E, Nakayama I, Osumi H, Ota Y, Takahari D, Chin K, Seimiya H, Yamaguchi K. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
Invest New Drugs, 38: 111-119, 2020.
4.Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib.
Cancer Sci, 111: 441-450, 2020.
5.Mizutani A, Seimiya H. Tankyrase promotes primary precursor miRNA processing to precursor miRNA.
Biochem Biophys Res Commun, 522: 945-951, 2020.
6.Okamoto K, Seimiya H. From the wings to the center stage of chromosomes.
J Biol Chem, 294: 17723-17724, 2019.
7.Mashima T, Iwasaki R, Kawata N, Kawakami R, Kumagai K, Migita T, Sano T, Yamaguchi K, Seimiya H. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.
Br J Cancer, 121: 846-856, 2019.
8.Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, Watanabe H, Honma T, Umehara T, Shirouzu M, Okue M, Kano Y, Watanabe T, Kitamura K, Shitara E, Muramatsu Y, Yoshida H, Mizutani A, Seimiya H, Yoshida M, Koyama H. Discovery of novel spiroindoline derivatives as selective tankyrase inhibitors.
J Med Chem, 62: 3407-3427, 2019.

研究２　治療薬耐性と微小環境適応に関わる腫瘍細胞社会ネットワークの解明
1.Okamoto Y, Saito T, Tani Y, Toki T, Hasebe A, Koido M, Tomida A. The kinase PERK represses translation of the G protein-coupled receptor LGR5 and receptor tyrosine kinase ERBB3 during ER stress in cancer cells.
J Biol Chem, In press, 2020.
2.Yanagitani N, Uchibori K, Koike S, Tsukahara M, Kitazono S, Yoshizawa T, Horiike A, Ohyanagi F, Tambo Y, Nishikawa S, Fujita N, Katayama R, Nishio M. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Cancer Sci, 111: 932-939, 2020.
3.Takahashi K, Seto Y, Okada K, Uematsu S, Uchibori K, Tsukahara M, Oh-Hara T, Fujita N, Yanagitani N, Nishio M, Okubo K, Katayama R. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Thorac Cancer, 11: 581-587, 2020.
4.Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata A, Shaw AT, Nishio M, Fujita N, Isoyama T. The new-generation selective ROS1/NTRK Inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Nature Commun, 10: 3604, 2019.
5.Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, Besse B, Yanagitani N, Friboulet L, Nishio M, Takeuchi K, Kawamoto H, Fujita N, Katayama R. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
J Exp Med, 216: 982-1000,2019.

研究３　腫瘍組織内におけるがん転移形質の獲得機構の解明と転移阻害薬の開発
1.Rayes J, Retzbach E, Sheehan S, Timmerman C, Goldberg G, Miyashita T, Ishii G, Yoneda K, Tanaka F, Takemoto A, Takagi S, Fujita N, Tsutsumi M, Krishnan H, Chalise L, Natsume A, Burkett P. Podoplanin, cancer, and inflammation.
J Clin Med, in press, 2020.

研究４　腫瘍細胞社会ネットワークを標的にした抗がんリード化合物評価系の開発と整備
1.Tsukada K, Shinki S, Kaneko A, Murakami K, Irie K, Murai M, Miyoshi H, Dan S, Kawaji K, Hayashi H, Kodama EN, Hori A, Salim E, Kuraishi T, Hirata N, Kanda Y, Asai T. Synthetic biology based construction of biological activity-related library focused on fungal decalin-containing diterpenoid pyrones.
Nature Commun, in press, 2020.
2.Matsumoto T, Akatsuka A, Dan S, Iwasaki H, Yamashita M, Kojima N. Synthesis and cancer cell growth inhibition effects of agetogenin analogs bearing ethylene glycol units for enhancing the water solubility.
Tetrahedron, 76: 131058, 2020.
3.Kitajima Y, Ishii T, Kohda T, Ishizuka M, Yamazaki K, Nishimura Y, Tanaka T, Dan S, Nakajima M. Mechanistic study of PpIX accumulation using the JFCR39 cell panel revealed a role for dynamin 2-mediated exocytosis.
Sci Rep., 9(1): 8666, 2019.
4.Kodaka A, Hayakawa Y, AlSayegh RJ, Yasuhara T, Tomoda H, Oku T, Dan S, Tsuiji M, Tsuji T. Stereoisomer-Specific Induction of G2/M Phase Arrest and Apoptosis by 9-(E,Z)-Hydroxyoctadecadienoic Acid in Mouse Lymphoma Cells.
Biol Pharm Bull., 42(6): 937-943, 2019.

論文

事業成果物名	2019年度 腫瘍細胞社会ネットワークを標的とした革新的がん治療薬の開発
ファイル	形式：DOCX　容量：31KB
事業成果物名	2019年度 腫瘍細胞社会ネットワークを標的とした革新的がん治療薬の開発
URL	http://www.zaidan.info/jigyo/2019/0000093820/jigyo_info.html